Changes in antidepressant metabolism and dosing across pregnancy and early postpartum - PubMed (original) (raw)

Clinical Trial

Changes in antidepressant metabolism and dosing across pregnancy and early postpartum

Dorothy K Sit et al. J Clin Psychiatry. 2008 Apr.

Abstract

Objective: Little information about the disposition of individual antidepressant drugs during pregnancy has been published. We examined the dose requirements and level-to-dose (L/D) ratios of citalopram, escitalopram, and sertraline during pregnancy and after birth.

Method: Women aged from 32 to 43 years with major depressive disorder according to the Structured Clinical Interview for DSM-IV Axis I Disorders participated in the study. Doses were charted across each week of gestation and post-partum. Samples were collected at 20, 30, and 36 weeks' gestation; delivery; and at 2 and 12 weeks postpartum. Plasma trough levels were obtained 8 to 15 hours after dose intake. Across pregnancy and postpartum, the mean dose-corrected plasma concentrations (L/D ratios) of S- and R-citalopram and S-sertraline, and the corresponding primary chiral metabolites S- and R-desmethylcitalopram and N-desmethylsertra-line were assessed. The samples were analyzed for concentrations of stereospecific parent drug and metabolites. The study was conducted from 2003 to 2006.

Results: Three women received citalopram, 2 women were treated with escitalopram, and 6 women received sertraline. In 4 of 5 subjects who received citalopram or escitalopram and 5 of 6 subjects who received sertraline, the L/D ratios for the stereoisomers of the parent compound and primary metabolite decreased between 20 weeks gestation and delivery, which reflects increased drug metabolism. By 12 weeks postpartum the L/D ratios were similar to those detected at 20 weeks gestation.

Conclusions: Our cases illustrate that dose requirements frequently increase during the second half of pregnancy to offset increased drug turnover and maintain optimal pharmacotherapy. These findings replicate and extend earlier published data with other antidepressants.

Trial registration: clinicaltrials.gov Identifier: NCT00279370.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Mean Drug Level-to-Dose (L/D) Ratios Across Childbearing for Citalopram-Treated Women

Figure 2

Figure 2

Mean Drug Level-to-Dose (L/D) Ratios Across Childbearing for Escitalopram-Treated Women

Figure 3

Figure 3

Mean Drug Level-to-Dose (L/D) Ratios Across Childbearing for Sertraline-Treated Women

Comment in

Similar articles

Cited by

References

    1. Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public Health Rep. 2001;116(suppl 1):32–40. - PMC - PubMed
    1. U.S. Food and Drug Administration. Pharmacokinetics in Pregnancy: Study Design, Data Analysis, and Impact on Dosing and Labeling. US Dept Health Human Services; 2004. October Issue, Guidance for Industry; pp. 1–14.
    1. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry. 1993;150:1541–1542. - PubMed
    1. Wisner KL, Perel JM, Peindl KS, et al. Effects of the postpartum period on nortriptyline pharmacokinetics. Psychopharmacol Bull. 1997;33:243–248. - PubMed
    1. Hostetter A, Stowe ZN, Strader JR, Jr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety. 2000;11:51–57. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources